Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer

To evaluate the efficacy and safety of immune checkpoint inhibitors, alone or in combination with chemotherapy, in people with advanced gastric and gastroesophageal junction adenocarcinoma in first and subsequent treatment lines.

This is a protocol.